Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Hims & Hers Health Stock Jumps Nearly 28% on Plans to Offer GLP-1 Weight-Loss Drugs
05:15pm, Monday, 20'th May 2024
Shares of Hims & Hers Health (HIMS) surged close to 28% Monday after the telehealth company said it would begin offering GLP-1 injections as part of its weight-loss package of drugs.
Hims & Hers rallies after announcing access to GLP-1 injections
12:23pm, Monday, 20'th May 2024
Hims & Hers Health Inc shares rocketed 31% higher on Monday after announcing it will provide access to injectable GLP-1 medications. These injections serve as a more affordable alternative to branded
Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings
12:01pm, Monday, 20'th May 2024
Hims & Hers Health Inc.'s stock HIMS, +32.81% jumped more than 30% Monday morning after the health and wellness platform said it would offer compounded GLP-1 drugs — products that the Food and Drug
Hims & Hers Health adds compounded GLP-1 injections to weight loss program
09:00am, Monday, 20'th May 2024
The GLP-1 market has faced supply constraints in recent months as the drugs like Ozempic and Wegovy skyrocket in popularity.
Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers
09:00am, Monday, 20'th May 2024
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving
Hims & Hers rallies after announcing access to GLP-1 injections
08:21am, Monday, 20'th May 2024
Hims & Hers Health Inc shares rocketed 31% higher on Monday after announcing it will provide access to injectable GLP-1 medications. These injections serve as a more affordable alternative to branded
GLP-1 Drug Development Market Pile-Up Continues
08:20am, Monday, 20'th May 2024
The mean weight loss in a Phase 1b trial of the GLP/GIP against CT-388 (once-a-week injection for 24 weeks) has just read out at 18.8%, with (apparently) no safety signals. Amgen sort-of-announced pos
Thomson Reuters Co. (NYSE:TRI) Shares Sold by Beacon Pointe Advisors LLC
07:32am, Monday, 20'th May 2024
Beacon Pointe Advisors LLC lessened its position in shares of Thomson Reuters Co. (NYSE:TRI – Free Report) (TSE:TRI) by 2.9% during the fourth quarter, according to the company in its most recen
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p
Q2 2024 EPS Estimates for Cresco Labs Inc. (OTCMKTS:CRLBF) Boosted by Alliance Global Partners
01:38am, Monday, 20'th May 2024
Cresco Labs Inc. (OTCMKTS:CRLBF – Free Report) – Analysts at Alliance Global Partners increased their Q2 2024 earnings per share (EPS) estimates for Cresco Labs in a research note issued o
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT May 19, 2024 12:50 PM EDT | Source: The Rosen Law
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
09:10am, Friday, 17'th May 2024
Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? KELOWNA, BC / ACCESSWIRE / May 17,
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
08:24am, Friday, 17'th May 2024
Wegovy and Zepbound are two of the hottest GLP-1 drugs available on the market right now. The field, however, could become more crowded as more companies develop rival treatments.
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity
01:10am, Thursday, 16'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib clinical trial of CT-388, a dual G
Healthy Returns: One in eight adults have taken Ozempic or other GLP-1s, survey says
02:35pm, Tuesday, 14'th May 2024
A wide swath of Americans are using GLP-1s despite shortages, a survey says. Meanwhile, Google DeepMind's new AI model can predict the structure of molecules.
